Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Vertex Nabs ENaC Inhibitors
by Lisa M. Jarvis
June 15, 2015
| A version of this story appeared in
Volume 93, Issue 24
Vertex Pharmaceuticals will pay Parion Sciences $80 million for access to epithelial sodium channel (ENaC) inhibitors for the treatment of cystic fibrosis. The deal includes P-1037, which is currently in a Phase II study. Vertex and Parion are also planning a study combining P-1037 with Vertex’s CF treatments lumacaftor and ivacaftor in people with two copies of the F508del mutation, the most common mutation driving the disease. Vertex says it will also explore the ENaC inhibitors as treatments for other pulmonary diseases.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter